Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status

PURPOSE: Glioblastoma is associated with especially poor outcome in the elderly. It is unclear if patients aged ≥80 years benefit from tumor-specific therapy as opposed to receiving best supportive care (BSC) only. METHODS: Patients with IDH-wildtype glioblastoma (WHO 2021), aged ≥80 years, and diag...

Descripción completa

Detalles Bibliográficos
Autores principales: Weller, Jonathan, Katzendobler, Sophie, Niedermeyer, Sebastian, Harter, Patrick N., Herms, Jochen, Trumm, Christoph, Niyazi, Maximilian, Thon, Niklas, Tonn, Joerg-Christian, Stoecklein, Veit M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322768/
https://www.ncbi.nlm.nih.gov/pubmed/37289281
http://dx.doi.org/10.1007/s11060-023-04362-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322768/
https://www.ncbi.nlm.nih.gov/pubmed/37289281
http://dx.doi.org/10.1007/s11060-023-04362-y

Ejemplares similares